Abstract
Abstract not available.
Highlights
MC2-01 cream is a novel topical treatment of psoriasis containing the active ingredients calcipotriene and betamethasone dipropionate (0.005% / 0.064% w/w, CAL/Betamethasone diproponate (BDP))
The phase 3, randomized, multicenter, investigator-blind, parallel-group trial evaluated the efficacy and safety of MC2-01 cream compared to MC2-01 vehicle and CAL/BDP TS in adult patients with psoriasis vulgaris on the body
Additional analysis of Physician’s Global Assessment (PGA) treatment success on the ITT population using multiple imputations showed that MC2-01 cream was superior to CAL/BDP TS at Week 4 (p
Summary
MC2-01 cream is a novel topical treatment of psoriasis containing the active ingredients calcipotriene and betamethasone dipropionate (0.005% / 0.064% w/w, CAL/BDP). MC2-01 cream is based on PADTM Technology contributing high penetration of the actives combined with excellent cosmetic elegance. Data from a phase 3 trial is presented comparing efficacy of MC2-01 cream to vehicle and to the comparator CAL/BDP topical suspension (“CAL/BDP TS”) in adults with mild to moderate psoriasis vulgaris on the body. The trial enrolled 796 patients at 55 clinical sites across the United States. Dual additive efficacy of CAL and BDP Improved safety profile compared to the individual actives alone.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
